LncRNA ANCR down-regulation promotes TGF-β-induced EMT and metastasis in breast cancer
Metrics: PDF 1420 views | HTML 1833 views | ?
Zhongwei Li1, Meichen Dong1, Dongmei Fan2, Pingfu Hou3, Hongyuan Li1, Lingxia Liu2, Cong Lin2, Jiwei Liu1, Liangping Su1, Lan Wu1, Xiaoxue Li2, Baiqu Huang2, Jun Lu2 and Yu Zhang1
1The Key Laboratory of Molecular Epigenetics of Ministry of Education (MOE), Northeast Normal University, Changchun, China
2The Institute of Genetics and Cytology, Northeast Normal University, Changchun, China
3Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, China
Yu Zhang, email: firstname.lastname@example.org
Keywords: lncRNA ANCR, TGF-β, EMT, RUNX2, metastasis
Received: January 20, 2017 Accepted: May 29, 2017 Published: June 27, 2017
Epithelial to mesenchymal transition (EMT) is a progression of cellular plasticity critical for development, differentiation, cancer cells migration and tumor metastasis. As a well-studied factor, TGF-β participates in EMT and involves in physiological and pathological functions of tumor progression. Accumulating evidence indicates that long noncoding RNAs(lncRNAs) play crucial roles in EMT and tumor metastasis. Here, we find that lncRNA ANCR participates in TGF-β1-induced EMT. By our ChIP and Real-time PCR assays, we reveal that TGF-β1 down-regulates ANCR expression by increasing HDAC3 enrichment at ANCR promoter region, which decreases both H3 and H4 acetylation of ANCR promoter. In addition, by western blot and transwell assays, we indicate that ectopic expression of ANCR partly attenuates the TGF-β1-induced EMT. Downstream, ANCR inhibits breast cancer cell migration and breast cancer metastasis by decreasing RUNX2 expression in vitro and in vivo. Thus, our study identifies ANCR, as a new TGF-β downstream molecular, is essential for TGF-β1-induced EMT by decreasing RUNX2 expression. These results implicate that ANCR might become a prognostic biomarker and an anti-metastasis therapy target for breast cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.